Eledon Pharmaceuticals (NASDAQ: ELDN) is one of 777 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Eledon Pharmaceuticals to related companies based on the strength of its analyst recommendations, valuation, earnings, profitability, institutional ownership, dividends and risk.
Earnings & Valuation
This table compares Eledon Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Eledon Pharmaceuticals||N/A||-$16.01 million||-0.77|
|Eledon Pharmaceuticals Competitors||$1.89 billion||$219.07 million||-5.16|
Volatility & Risk
Eledon Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals’ competitors have a beta of 0.40, indicating that their average stock price is 60% less volatile than the S&P 500.
Institutional & Insider Ownership
44.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 2.2% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 15.4% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Eledon Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eledon Pharmaceuticals Competitors||-3,540.56%||-189.52%||-30.06%|
This is a summary of current ratings and price targets for Eledon Pharmaceuticals and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eledon Pharmaceuticals Competitors||4276||16613||36699||747||2.58|
Eledon Pharmaceuticals currently has a consensus price target of $34.00, indicating a potential upside of 105.56%. As a group, “Pharmaceutical preparations” companies have a potential upside of 31.83%. Given Eledon Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Eledon Pharmaceuticals is more favorable than its competitors.
Eledon Pharmaceuticals beats its competitors on 7 of the 13 factors compared.
Eledon Pharmaceuticals Company Profile
Eledon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.